Compare Biogen Inc (BIIB) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Verisign, Inc. — how do they compare? Biogen Inc trades at $190.87 (market cap $28.34B), while Verisign, Inc. trades at $268.9 (market cap $24.47B). The key difference: Biogen Inc is the larger of the two by market cap, and Verisign, Inc. pays a 1.21% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | VRSN | |
|---|---|---|
Market Cap | $28.34B | $24.47B |
Sector | Health | Technology |
52-Week High | $216.63 | $310.00 |
52-Week Low | $122.68 | $211.49 |
Enterprise Value | $30.62B | $25.70B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
VeriSign (VRSN) trades at $270.31, up 0.07% with a bullish technical outlook. The stock shows strong fundamentals with 2025 revenue of $1.66B, net income of $825.7M, and exceptional 49.96% net margin. Recent Q1 2026 earnings beat expectations at $2.34 EPS. Analyst consensus is bullish with 57% buy ratings and $327.67 price target, representing 21% upside potential. The company maintains its monopoly position in .com/.net domain registry with predictable revenue growth.
VRSN presents a compelling investment case with stable cash flows and dominant market position, though trading at premium valuations (P/E 29.87). Key risks include contract renewals, AI disruption potential, and high debt levels. The upcoming Q2 2026 earnings report on July 23 will be critical for validating growth trajectory. Current levels offer attractive entry for long-term investors seeking defensive tech exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
